Безопасность и эффективность терапии современными препаратами идиопатического легочного фиброза (обзор литературы)
Аннотация
В настоящем обзоре литературы рассмотрены вопросы эффективности и безопасности терапии ингибиторами тирозинкиназ и пирфенидоном при идиопатическом легочном фиброзе. Подробно освещены результаты рандомизированных исследований последних лет. Рассмотрена эффективность приема ингибиторов тирозинкиназ по следующим ключевым точкам исследований: годовой темп снижения жизненной емкости легких, тест 6-минутной ходьбы, качество жизни пациента и частота обострений. Системный поиск литературы проводился по базам данных Scopus, Web of Science, MedLine, elibrary и другим.
Об авторе
Е. А. Стрельцов
Карагандинский государственный медицинский университет
Казахстан
Интерн 6 курса. Направление - внутренние болезни.
Казахстан
Интерн 6 курса. Направление - внутренние болезни.
Список литературы
1. Bonella F., Stowasser S., Wollin L.. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. // Drug Des Devel Ther. – 2015. - V.9. - P.6407-19. doi: 10.2147/DDDT.S76648 http://bmjopenrespres.bmj.com/content/4/1/e000192
2. Richeldi L., du Bois R.M., Raghu G., Azuma A., Brown K.K., Costabel U. et all. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. // N Engl J Med. – 2014. – V.370(22). – P.2071-82. doi: 10.1056/NEJMoa1402584
3. http://www.nejm.org/doi/full/10.1056/NEJMoa1402584
4. Zhao H., Bian H., Bu X., Zhang S., Zhang P., Yu J. et all. Targeting of Discoidin Domain Receptor 2 (DDR2) Prevents Myofibroblast Activation and Neovessel Formation During Pulmonary Fibrosis. // Mol Ther. – 2016. – V.24(10). – P.1734-1744. doi: 10.1038/mt.2016.109
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112036/
6. Hutchinson J., Fogarty A., Hubbard R., McKeever T.. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. // Eur Respir J. - 2015. – V.46(3). – P.795–806. doi: 10.1183/09031936.00185114
7. http://erj.ersjournals.com/content/46/3/795.long
8. Raghu G. , Wells A.U., Nicholson A.G., Richeldi L., Flaherty K.R., Le Maulf F. et all. Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. // Am J Respir Crit Care Med. – 2017. – V.195(1). – P.78-85. doi: 10.1164/rccm.201602-0402OC
9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214917/
10. Kim K.K., Sisson T.H., Horowitz J.C.. Fibroblast growth factors and pulmonary fibrosis: it's more complex than it sounds. // J Pathol. – 2017. – V.241(1). – P.6-9. doi: 10.1002/path.4825
11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499705/
12. Vittal R., Zhang H., Han M.K., Moore B.B., Horowitz J.C., Thannickal V.J. et all. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. // J Pharmacol Exp Ther. – 2007. – V.321(1). – P.35-44.
13. http://jpet.aspetjournals.org/content/321/1/35.long
14. Ackermann M., Kim Y.O., Wagner W.L., Schuppan D., Valenzuela C.D., Mentzer S.J. et all. Effects of nintedanib on the microvascular architecture in a lung fibrosis model. // Angiogenesis. – 2017. – V.20(3). – P.359-372. doi: 10.1007/s10456-017-9543-z
15. https://link.springer.com/article/10.1007%2Fs10456-017-9543-z
16. Cottin V.. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis. // Expert Opin Drug Saf. – 2017. – V.16(7). – P.857-865. doi: 10.1080/14740338.2017.1338268
17. http://www.tandfonline.com/doi/abs/10.1080/14740338.2017.1338268?journalCode=ieds20
18. Huang J., Maier C., Zhang Y., Soare A., Dees C., Beyer C. et all. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. // Ann Rheum Dis. – 2017. V.76(11). – P.1941-1948. doi: 10.1136/annrheumdis-2016-210823
19. Sato S., Shinohara S., Hayashi S., Morizumi S., Abe S., Okazaki H. et all. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. // Respir Res. – 2017. – V.18(1). – P.172. doi: 10.1186/s12931-017-0654-2
20. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603061/
21. Mazzei M.E., Richeldi L., Collard H.R.. Nintedanib in the treatment of idiopathic pulmonary fibrosis.// Ther Adv Respir Dis. – 2015. – V.9(3). – P.121-9. doi: 10.1177/1753465815579365
22. http://journals.sagepub.com/doi/abs/10.1177/1753465815579365?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
23. Huang Z., Li H., Zhang Q., Tan X., Lu F., Liu H. et all. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis. // Drug Des Devel Ther. – 2015. – V.9. – P.4319-28. doi: 10.2147/DDDT.S83055
24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532346/
25. Hostettler K.E., Zhong J., Papakonstantinou E., Karakiulakis G., Tamm M., Seidel P. et all. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. // Respir Res. – 2014. – V.15. – P.157. doi: 10.1186/s12931-014-0157-3
26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4273482/
27. Richeldi L., Costabel U., Selman M., Kim D.S., Hansell D.M., Nicholson A.G.. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. // N Engl J Med. – 2011. –V.365(12). – P.1079-87. doi: 10.1056/NEJMoa1103690
28. http://www.nejm.org/doi/full/10.1056/NEJMoa1103690
29. Hinz B., Phan S.H., Thannickal V.J., Prunotto M., Desmoulière A., Varga J. et all. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. // Am J Pathol. – 2012. – V.180(4). – P.1340-55. doi: 10.1016/j.ajpath.2012.02.004
30. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640252/
31. Booth A.J., Hadley R., Cornett A.M., Dreffs A.A., Matthes S.A., Tsui J.L. et.all. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. // Am J Respir Crit Care Med. – 2012. – V.186(9). – P.866-76. doi: 10.1164/rccm.201204-0754OC
32. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530219/
33. Valiathan R.R., Marco M., Leitinger B., Kleer C.G., Fridman R.. Discoidin domain receptor tyrosine kinases: new players in cancer progression. // Cancer Metastasis Rev. – 2012. –V.31(1-2). – P.295-321. doi: 10.1007/s10555-012-9346-z
34. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351584/
35. Leitinger B., Kwan A.P.. The discoidin domain receptor DDR2 is a receptor for type X collagen. // Matrix Biol. – 2006. – V.25(6). – P.355-64.
36. http://www.sciencedirect.com/science/article/pii/S0945053X06000588
37. Maeyama M., Koga H., Selvendiran K., Yanagimoto C., Hanada S., Taniguchi E. et all. Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition. // Cancer. – 2008. – V.113(10). – P.2823-31. doi: 10.1002/cncr.23900
38. http://onlinelibrary.wiley.com/doi/10.1002/cncr.23900/abstract;jsessionid=E6E40ED667B5C303D44063FBD23E4320.f02t04
39. Nalysnyk L., Cid-Ruzafa J., Rotella P., Esser D. et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. // Eur Respir Rev. – 2012. - V.21(126). – P.355-61. doi: 10.1183/09059180.00002512
40. http://err.ersjournals.com/content/21/126/355.long
41. Richeldi L., Rubin A.S., Avdeev S., Udwadia Z.F., Xu Z.J.. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. // BMC Med. - 2015 V.13. – P.237. doi: 10.1186/s12916-015-0495-0
42. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581420/
43. Oku H., Shimizu T., Kawabata T., Nagira M., Hikita I., Ueyama A. et all. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. // Eur J Pharmacol. – 2008. – V.590(1-3). – P.400-8. doi: 10.1016/j.ejphar.2008.06.046
44. http://www.sciencedirect.com/science/article/pii/S0014299908006389
45. Liu Y., Lu F., Kang L., Wang Z., Wang Y.. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. // BMC Pulm Med. – 2017. – V.17(1). – P.63. doi: 10.1186/s12890-017-0405-7
46. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395978/
47. Ley B., Swigris J., Day B.M., Stauffer J.L., Raimundo K., Chou W. et all. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. // Am J Respir Crit Care Med. – 2017. – V.196(6). – P.756-761. doi: 10.1164/rccm.201701-0091OC
48. http://www.atsjournals.org/doi/abs/10.1164/rccm.201701-0091OC?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&
49. Hui Ren, MD, Kai Wang, MD, Hao Yang, PHD, and Lingyun Gao, MD. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis. // Saudi Med J. -2017. – V.38(9). – P.889–894.doi: 10.15537/smj.2017.9.19349
50. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654021/
51. Nathan S.D., Albera C., Bradford W.Z., Costabel U., Glaspole I., Glassberg M.K. et all. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. // Lancet Respir Med. – 2017. – V.5(1). – P.33-41. doi: 10.1016/S2213-2600(16)30326-5
52. http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30326-5/fulltext
53. Lehtonen S.T., Veijola A., Karvonen H., Lappi-Blanco E., Sormunen R., Korpela S. et all. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. // Respir Res. – 2016. – V.17. – P.14. doi: 10.1186/s12931-016-0328-5
54. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743320/
55. Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K. et all. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. // Am J Respir Crit Care Med. – 2011. – V.183(6). – P.788-824. doi: 10.1164/rccm.2009-040GL
56. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450933/
Для цитирования:
Стрельцов Е.А. Безопасность и эффективность терапии современными препаратами идиопатического легочного фиброза (обзор литературы). Медицинский вестник Юга России. 2018;9(1):17-22. https://doi.org/10.21886/2219-8075-2018-9-1-17-22
For citation:
Strel’tsov E.A. Safety and efficiency of therapy with modern preparations of idiopathic pulmonary fibrosis. Medical Herald of the South of Russia. 2018;9(1):17-22. (In Russ.) https://doi.org/10.21886/2219-8075-2018-9-1-17-22
Просмотров: 242
Послать статью по эл. почте 